Reuters logo
BRIEF-RXI Pharmaceuticals announces initiation of its consumer testing program with RXI-231
June 12, 2017 / 11:14 AM / 3 months ago

BRIEF-RXI Pharmaceuticals announces initiation of its consumer testing program with RXI-231

June 12 (Reuters) - Rxi Pharmaceuticals Corp

* RXI Pharmaceuticals Corp- rxi pharmaceuticals announces initiation of its consumer testing program with rxi-231

* RXI Pharmaceuticals - ‍initiation of consumer/functional testing program with rxi-231, cosmetic ingredient based on sd-rxrna that targets tyrosinase​

* RXI Pharmaceuticals Corp - ‍consumer testing program will evaluate use and consumer acceptability of rxi-231​

* RXI Pharmaceuticals - anticipate duration of combined studies under this program to be about 3-4 months enabling us to report results in q4 of this year Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below